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A retrospective multicentric study was performed from a one-
year (2005) registry of patients from ﬁve primary care centres in
Spain. Inclusion criteria were as follows: mild to moderate HT
as per JNC-VII, British Hipertensión-Society; and DL as per
NCEP-ATP III. Compliance was estimated by the relationship
between the amount of dispensed and prescribed pills. Demo-
graphic variables, comorbidities, clinical parameters and sanitary
resources were registered. A bivariant analysis and a multiple
lineal regression analysis were done to correct the model.
RESULTS: Compliance was estimated from the total sample of
15,606 patients (HT: 41.7%; DL: 23.1%; HT/DL: 35.2%), in
85.9% (CI = 85.4–86.4%), 81.6% (CI = 81.0–82.2%) and
84.9% (CI = 84.3–85.5%) respectively (p = 0.000; Scheffé).
Explanatory variables of a better compliance in the multivariate
analysis were (beta = 0.832; t = 59.1; p = 0.000): a) direct rela-
tionship: age, labour inactivity, drug price, and b) indirect rela-
tionship: glycemia, triglycerides, LDL and number of active
principles used (p = 0.000). CONCLUSION: Dyslipidemic
patients show a worse compliance than hypertensive patients,
and dyslipidemia worsened global compliance in hypertensive
patients. Certain clinical parameters of control, the age of the
patient and the drug group are related to compliance in daily
medical practice.
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OBJECTIVES: Therapeutic compliance (TC) is related to risk
control in the hypertensive patient. Nevertheless there is no much
information on how the improvement of TC impacts on cardio-
vascular risk factors (CVRF), particularly on lipid parameters,
in the Spanish hypertensive patients. To analyze the relationship
among TC improvement (estimated by the relationship between
amount of drug dispensed and amount of drug prescribed), and
the variations in LDL-cholesterol (LDLc) and HDL-cholesterol
(HDL-c) levels. METHODS: Hypertensive patients from ﬁve
Spanish primary care centres, who had registered values of LDLc
and HDLc, between 2004 and 2005, were retrospectively
studied. Changes in TC, LDLc and HDLc were calculated
between mentioned years. Correlation between: a) changes in TC
and HDL, and b) changes in TC and HDL, were calculated using
the Spearman’s Rho test. RESULTS: Of the 6960 hypertensive
patients, 5094 had registered HDL-c levels in 2004 and 2005.
An increase in TC of 3.8% (DE:17.7%) was demonstrated. An
inverse and statistically signiﬁcant relationship between LDLc
and TC (p = 0.003) was demonstrated. No relationship was
found between TC improvement and HDLc (p = 0.9456) CON-
CLUSIONS: In the Spanish hypertensive population, CT
improvements are associated to a decrease in LDLc levels, with
no impact on HDL. Available treatments are not effective enough
to improve HDLc levels in the Spanish hypertensive patient.
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OBJECTIVE: Blood pressure control can be difﬁcult to achieve
in hypertension, often requiring combination pharmacotherapy.
A variety of approaches are available, including ﬁxed dose com-
binations (FDC) versus individual components (IC). The purpose
of this analysis was to assess combination valsartan and hydro-
cholorthiazide (HCTZ) therapy in previously antihypertensive
naïve patients. METHODS: A national database of insured
patients ages 18 & older with hypertension were evaluated for
combination valsartan and HCTZ use initiated within 180 days
of each other. Patients had at least two claims for this combina-
tion of pharmacotherapy within one year of their ﬁrst prescrip-
tion. Eligibility included continuous enrollment 110 days prior
to ﬁrst prescription and 365 days following dual therapy. Eligi-
ble patients were antihypertensive naïve 110 days prior to study
drug initiation. Combination pharmacotherapy persistency at
365 days was calculated and sensitivity analysis was performed
for the length of reﬁll gaps. RESULTS: There were 2,022,578
unique patients age18 years or older identiﬁed with hypertension
ICD-9 codes (401.0, 401.1, 401.9, 402.1 & 402.9). After apply-
ing study criteria there were 8711 eligible patients; 8150 FDC
and 561 IC. In assessing ongoing persistence, patients could not
have a reﬁll gap in excess of 120% of previous prescription day’s
supply. FDC persistency was 54% (4362/8150) compared to
19% (109/561) for IC at 365 days (p < 0.0001). Using a more
stringent threshold (80% days supply), FDC was 44%
(3623/8150) vs. IC 16% (91/561) p < 0.0001. Increasing the
threshold (160% days supply) the FDC was 59% (4821/8150)
vs. IC 21% (119/561) p < 0.0001. CONCLUSIONS: Use of FDC
is more common (93.5%) than individual components for this
previously naïve antihypertensive population. The ﬁxed dose
combination therapy group was shown to have signiﬁcantly
better persistence at 365 days vs. the individual components
group, which proved to be quite robust following a sensitivity
analysis.
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Reduction of cardiovascular risk frequently requires the 
co-administration of multiple antihypertensive (AH) and lipid
lowering (LL) drugs. Fixed combinations of two drugs could
improve daily compliance by simplifying the treatment regimen.
OBJECTIVE: To assess which antihypertensive patients might
beneﬁt from a combination of AH and LL drugs. METHODS:
Hypertensive patients (>=30 years plus >=3 cardiovascular risk
factors or events (CVD), experienced or new users of antihyper-
tensive drugs between June 2003-June 2004)were selected from
the IPCI database in The Netherlands. A written questionnaire
was administered in October 2005 regarding reasons for non-
compliance, likelihood of missing a dose if two pills would be
combined in one, and self-reported medication-taking. Percent-
age of days covered (PDC) with AH medication was calculated
from the prescription records. RESULTS: A total of 729 out of
1473 patients responded, 101 were new users of antihyperten-
sive drugs, 349 had CVD. Respondents (75% male, median age
63 years) used on average 3 drugs, and 40% used LL drugs at
start of follow-up. Side effects, lack of efﬁcacy, and forgetting
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scored highest as reasons for not taking medications as pre-
scribed. The median PDC for antihypertensive drugs was 57%,
less than 40% had PDC >80%, with newly treated hypertensive
patients commonly =<80% PDC. 35% would be less likely or
much less likely to miss a dose if two pills would be combined
in one tablet, this likelihood was independent of CVD, experi-
enced or new use and calculated PDC levels. Perceived likeliness
to beneﬁt from a combined tablet was signiﬁcantly higher in
persons taking fewer AH drugs, and patients self-reporting
taking =<20% of doses. CONCLUSION: Patients newly treated
with antihypertensive drugs and additional cardiovascular risk
factors may beneﬁt most from a ﬁxed combination of two car-
diovascular risk reducing drugs in one pill since they express
more partial adherence and use fewer tablets.
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OBJECTIVES: Noncompliance and non-persistence with long-
term medication is a serious world-wide problem that leads to
compromised health beneﬁts and serious economic conse-
quences. A systematic literature review was conducted to
compare rates of compliance and persistence among studies 
of treatments for hypertension, dyslipidemia, and diabetes.
METHODS: A search of the literature (2000–2005) was focused
on publications that provided a numeric measure of medication
compliance and/or persistence, an adequate description of
methods, and numeric compliance and/or persistence rates for
antihypertensives (AHT), lipid-lowering therapy (LLT), or oral
antidiabetics (OAD). Studies were classiﬁed according to their
source of data into pharmacy claims and electronic monitors
(Medication Event Monitoring System, MEMS), and by study
design into retrospective and prospective studies. Results
reported as medication possession ratio (MPR) were extracted
and averaged over the treatment arms of the studies. Compliance
rates were compared across study design and treatment class.
RESULTS: The literature review resulted in 139 studies assess-
ing treatment with one or more targeted medications: AHT =53,
LLT =32, OAD =35, multiple treatments =19. Twelve-month
compliance rates averaged 67% for AHT, 74% for LLT, and
76% for OAD drugs (overall 72 ± 18%).Compliance rates aver-
aged 79% among prospective and 71% among retrospective
studies (NS). Persistence estimates at 12 months from 22 studies
ranged between 35% and 92% (mean 63 ± 18%). Thirty-ﬁve
percent of the reports related compliance to treatment outcomes.
Similar proportions were observed across classes. The propor-
tion of MEMS studies reporting outcomes related to compliance
or persistence was higher than studies based on pharmacy claims:
clinical consequences (52% vs. 18%), health care utilization
(14% vs 4%), and lower for no outcome data (33% vs. 78%)
(p = 0.004). CONCLUSION: These data indicated comparable
compliance and persistence rates across treatments for hyper-
tension, dyslipidemia, and diabetes with three-fourths of med-
ication taken as prescribed and two-thirds of patients continuing
for one year.
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OBJECTIVES: Assess prevalence and discontinuation rates 
of antidyslipidemic therapy in patients with dyslipidemia.
METHODS: We conducted a retrospective cohort study using a
large US national database of electronic medical records con-
taining diagnosis, lab and medication information. Users of 
antidyslipidemics were identiﬁed. Prevalence of six classes of
antidyslipidemics was described and one-year discontinuation
rate was calculated. Logistic regression model was used to eval-
uate factors affecting drug discontinuation. RESULTS: We iden-
tiﬁed 153,505 patients who started antidyslipidemic therapy
from 1997 to 2004 and were followed for one year after drug
initiation. Among 214,440 distinct treatment regimen initiations,
79.5% were statins, with atorvastatin (52.7%) and simvastatin
(24.0%) being the most frequently prescribed. Prevalence of
other classes of antidyslipidemics was: 8.8% for ﬁbrates, 5.3%
for cholesterol absorption inhibitors, 3.3% for niacin, 2.7% for
bile acid-binding resins, and 0.5% for combination formula-
tions. One-year discontinuation rate was 28.6% for statins,
31.8% for cholesterol absorption inhibitors, 34.1% for ﬁbrates,
40.7% for combination formulations, 44.7% for niacin, and
50.1% for bile acid-biding resins. Logistic regression showed
that statin users were less likely to stop therapy than patients on
other classes (odds ratio (OR): 0.63). Surprisingly, patients with
coronary hear disease (OR: 1.22) and diabetes (OR: 1.13) were
more likely to discontinue treatment than patients without those
conditions; high LDL-C or TG and low HDL-C were also found
to be associated with higher rates of medication discontinuation
at one year. CONCLUSIONS: Our study showed that signiﬁcant
variation exists in medication discontinuation among different
classes of antidyslipidemics. Medications targeting to raise HDL-
C or lower TG had higher discontinuation rate, implying that
there were unmet needs for the treatment of abnormal HDL-C
or TG. High discontinuation rate for patients at high risk for
cardiovascular disease was a major concern. Further studies are
needed to assess the consequences and implications of medica-
tion discontinuation.
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OBJECTIVE: To evaluate the impact of patient beliefs on med-
ication non-adherence for the purpose of crafting medication
adherence messages for disease management programs.
METHODS: In late 2005, 5630 respondents to the Thomson
Medstat PULSE health behavior survey, a nationally representa-
tive U.S. survey, reported having high cholesterol. Respondents
received additional cholesterol-speciﬁc questions beyond demo-
graphic/clinical questions already part of the survey. Beliefs
about the necessity of and concerns about taking their medica-
tions were assessed via ﬁve likert-scale questions each with
summed scores ranging between ﬁve and 25. A cut-point of 15
was used to identify high versus low necessity or concerns. Four
patient segments resulted representing high necessity/high
concern, low necessity/high concern, low necessity/low concern,
